Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Biogen Seeks FDA Approval for a Higher Dosing Regimen of Spinraza for Spinal Muscular Atrophy
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken 14 days apart can deliver significant clinical benefits in patients with spinal muscular atrophy.
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular Development Unit at Biogen.
FDA and EMA Accepts Applications for New Nusinersen Regimen
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
FDA and EMA review Biogen's higher dose SMA drug
CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, has reached a pivotal phase as regulatory agencies in the United States and Europe are now reviewing a higher dose regimen of nusinersen,
Biogen Says FDA And EMA Accept Applications For Higher Dose Regimen Of Nusinersen In SMA
Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New
FDA and EMA accept filings for higher dose of nusinersen in SMA
The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen,
2d
on MSN
Ionis stock rises on FDA, EMA nod for SMA drug dose increase
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...
SMA
4d
Woman gives birth to healthy child while on Spinraza treatment
A woman with SMA type 3 became pregnant while on Spinraza treatment and gave birth to a healthy child, per a case report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Indicted for insurrection
Los Angeles wildfire updates
38 hurt on United flight
ISR to get 2K-pound bombs
Shifts view on COVID origins
US has not stopped aid
Fires inspectors general
Wins US figure skating title
Smuggling deaths guilty plea
Nets retire No. 15 jersey
Recalls over 80,000 SUVs
IA immigration law blocked
Woman arrested in shooting
Jets hire Mougey as GM
153 war detainees freed
Sentenced to 17+ years
Hack impacted 190M
Pandas make public debut
Wins first Grand Slam title
Wallen announces tour
DOJ drops case
‘Walk It Out’ rapper dies
Assault trial begins
Carroll to coach Raiders
Jabrill Peppers testifies
PETA activists arrested
Consumer sentiment falls
Manson won't face charges
Barred from entering DC
Escaped monkeys captured
Target ending its DEI goals
Confirmed to lead Pentagon
Related topics
Spinal muscular atrophy
Food and Drug Administration
Biogen
European Medicines Agency
Feedback